Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest update is out from MYND Life Sciences ( (TSE:MYND) ).
MYND Life Sciences has announced the issuance of 4,000,001 common shares at a price of $0.71 per share to settle a $3.5 million CDN debenture. This strategic move is seen as a significant step for MYND, enabling collaboration with the investment community to address the challenges faced by individuals suffering from major depressive disorder. The financial implications of this issuance will be detailed in their upcoming financial statements.
More about MYND Life Sciences
MYND Life Sciences Inc. is a clinical-stage life sciences company specializing in the development and commercialization of drug therapies and diagnostics aimed at enhancing the monitoring and treatment of depression. The company focuses on Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD) and is developing a proprietary biomarker test with the aim of becoming the first to market in this area.
YTD Price Performance: -80.0%
Average Trading Volume: 4,605
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.66M
See more insights into MYND stock on TipRanks’ Stock Analysis page.
